Vt-Ebv-N
Extranodal NK/T-cell Lymphoma
ViGenCell Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
53 Active assets in the Extranodal NK/T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PEGASPARGASE CStone Pharmaceuticals | Phase 4 | BBB |
DEXAMETHASONE Mingzhi Zhang | Phase 4 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Centre, Singapore | Phase 4 | BBB |
ETOPOSIDE Tarapeutics Science Inc. | Phase 4 | BB |
Tucidinostat Ruijin Hospital | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →